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Abstract The purpose of this study was to gain more
insight into the mechanism of action of pasireotide in
patients who completed the PAOLA study. PAOLA was a
24-week, Phase III, randomized, three-arm study of pasir-
eotide LAR 40 and 60 mg versus octreotide LAR 30 mg or
lanreotide Autogel 120 mg in patients with inadequately
controlled acromegaly. The current work was a planned
exploratory objective of the PAOLA study that evaluated
changes in levels of growth hormone (GH), insulin-like
growth factor 1 (IGF-1), IGF-binding proteins (IGFBP-2,
IGFBP-3), glycated haemoglobin (HbA1c) and fasting
plasma glucose (FPG) in each treatment arm. Responders
to pasireotide LAR (mean GH levels\2.5 lg/L and normal
IGF-1 levels at 24 weeks) had lower GH and IGF-1 levels
at baseline (GH 5.1 ng/mL, IGF-1 519 ng/mL) than non-
responders (GH 7.9 ng/mL, IGF-1 672 ng/mL). Frequency
of hyperglycaemia after pasireotide treatment was similar
in responders and non-responders and depended more on
the baseline FPG level. 47 % of all patients treated with
pasireotide LAR (40 or 60 mg) did not receive antidiabetic
medication at any time during this study. This is the first
study to evaluate the treatment effect of pasireotide on key
hormonal and glycaemic biomarkers and to identify
potential predictors of pasireotide-associated hypergly-
caemia. Pre-treatment glucose status may be predictive of
the development of pasireotide-associated hyperglycaemia.
A large subset of patients with acromegaly does not
experience major disturbances in glucose homeostasis
while receiving pasireotide LAR.
Keywords PAOLA  Pasireotide  HbA1c  Glucose 
Hyperglycaemia  Acromegaly
Introduction
Medical therapy targeting somatostatin receptors is a
mainstay treatment of disorders associated with hormone
hypersecretion, such as acromegaly [1].
Five somatostatin receptor subtypes (SSTR1–5) have
been identified [2]. In acromegaly, both first-generation
somatostatin analogues, octreotide and lanreotide, exert
their pharmacological effects mainly by binding to SSTR2
and to a lesser extent to SSTR5 [3], which are both
expressed by most growth hormone (GH)-secreting pitu-
itary adenomas [4]. The excess GH and insulin-like growth
factor 1 (IGF-1) levels associated with acromegaly are
suppressed in most patients following treatment with
somatostatin analogues [5]. However, despite the clinical
success of octreotide and lanreotide therapy in the treat-
ment of acromegaly, approximately half of patients remain
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inadequately controlled [5] and are exposed to the delete-
rious effects of hormone hypersecretion, including signifi-
cant co-morbidities, notably diabetes mellitus, increased
mortality risk, and diminished quality of life [1]. Thus,
alternative therapeutic options are needed.
Pasireotide, a multireceptor-targeted somatostatin ana-
logue, has a high binding affinity for SSTR1, 2, 3, and 5
(exhibiting a 39-fold higher binding affinity for SSTR5
compared with octreotide [6]), with more profound sup-
pression of GH and IGF-1 than octreotide [7, 8]. In a
randomized, Phase III study in medically naı¨ve patients
with acromegaly, pasireotide LAR demonstrated superior
efficacy over octreotide LAR [9]. More recently, in the
PAOLA study, pasireotide LAR provided superior efficacy
versus continued treatment with octreotide LAR or lan-
reotide Autogel (control group) in patients with inade-
quately controlled acromegaly [10]. In both of these
studies, the safety profile of pasireotide LAR was generally
similar to that of first-generation somatostatin analogues,
except for the frequency and degree of hyperglycaemia.
Here, we report the results of a planned exploratory
objective of the PAOLA study. To gain more insight into
the mechanism of action of pasireotide in patients with
acromegaly inadequately controlled with first-generation
somatostatin analogues, changes in the clinically estab-
lished efficacy biomarkers GH and IGF-1, as well as other
biomarkers (IGF-binding protein [IGFBP]-2/3, glucose and
glycated haemoglobin [HbA1c]), were assessed after
pasireotide LAR treatment. Additionally, baseline levels of




Male and female patients aged C18 years with inade-
quately controlled acromegaly, defined as mean
GH[ 2.5 lg/L and IGF-1[ 1.3 times the sex- and age-
adjusted upper limit of normal (ULN), were enrolled in this
study. All patients had received treatment with octreotide
LAR 30 mg or lanreotide Autogel 120 mg for at least
6 months prior to screening. Patients could have received
prior surgery [10].
Study design
PAOLA was a prospective, multicentre, randomized, par-
allel-group study. The study design has been described
more fully elsewhere [10]. Briefly, after a 4-week screen-
ing period, patients were randomized to receive double-
blind pasireotide LAR 40 mg every 28 days for 24 weeks,
or double-blind pasireotide LAR 60 mg every 28 days for
24 weeks, or to continue on the same treatment with open-
label octreotide LAR 30 mg or lanreotide Autogel 120 mg
every 28 days for 24 weeks (active control group). Tran-
sient dose decreases were permitted for tolerability issues
in all treatment arms.
Study objectives
In the PAOLA study, the primary objective was to compare
the proportion of patients achieving biochemical control,
defined as mean GH levels\2.5 lg/L and normalization of
sex- and age-adjusted IGF-1 at 24 weeks, with pasireotide
LAR 40 mg and pasireotide LAR 60 mg separately versus
continuing the same treatment with octreotide LAR 30 mg
or lanreotide Autogel 120 mg. The main secondary end-
point was the proportion of patients achieving normaliza-
tion of sex- and age-adjusted IGF-1 at 24 weeks. The
outcomes are fully described elsewhere [10].
The objectives of the current work were to assess
changes in hormonal biomarkers (GH, IGF-1, IGFBP-2,
and IGFBP-3) and glucose homeostasis biomarkers (fasting
plasma glucose [FPG] and HbA1c) over time by treatment,
GH/IGF-1 response status, and the use of antidiabetic
medication.
Biochemical assessments
Blood samples for assessment of total IGF-1 were taken at
the same visits as for the assessment of mean GH level,
which was at screening, baseline, week 12, and week 24
(study completion). In addition, the mean IGF-1 level was
also assessed at week 4. All blood samples were taken
before the administration of study drug. Samples were
analysed as follows: GH was assessed as the mean of an
average of five individual measurements taken pre-dose at
0, 30, 60, 90, and 120 min within a 2-h time period after
1 h at rest at the hospital and was measured using the
Siemens Immulite 2000 S/N 1832 assay by a central con-
tract research organization (Quest Diagnostics Clinical
Trials, Valencia, CA, USA). IGF-1 and IGFBP-3 were
analysed from individual serum samples using the Siemens
Immulite 2000 S/N 1832 IGF-1 assay and the DPC
Immulite 2000 IGFBP-3 assay, respectively (Quest Diag-
nostics Clinical Trials, Valencia, CA, USA); IGFBP-2 was
analysed in serum using the R&D Systems IGFBP-2
enzyme-linked immunosorbent assay (ELISA) kit
(Cat#DY674; BioAgilytix Labs, Durham, NC, USA); and
FPG and HbA1c were centrally analysed (Quest Diagnos-
tics Clinical Trials, Valencia, CA, USA) by spectropho-
tometry using an Olympus AU 640/2700/5400 analyser and
by high-performance liquid chromatography (HPLC) using
a TOSOH G7/G8 automated HPLC analyser, respectively.
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Statistical analyses
The PAOLA study was not powered to assess specific
biomarker-related hypotheses, so the statistical analyses of
biomarker data should be considered as hypothesis driven
and exploratory in nature. Analyses were conducted on
patients who had available samples and who completed this
study. Time profiles of GH, IGF-1, IGFBP-2, IGFBP-3,
FPG, and HbA1c levels were analysed together and sepa-
rately in relevant subgroups of patients as follows: patients
who were responders (GH\ 2.5 lg/L and normal IGF-1)
or non-responders (GH C 2.5 lg/L and/or IGF-1[ULN)
at week 24; patients who did not receive antidiabetic
medication at any time during the study; patients who were
receiving antidiabetic medication at baseline; patients who
initiated antidiabetic medication during the study (i.e. post-
baseline); and patients with baseline FPG[ 100 and
B100 mg/dL. Hyperglycaemia was defined as one post-
baseline FPG measurement of C126 mg/dL or receiving
antidiabetic medication at any time during this study.
For biomarkers showing evidence of a skewed distri-
bution, summaries of natural-log-transformed values, geo-
metric means or medians were reported instead of
arithmetic means. GH, IGF-1, IGFBP-2 and IGFBP-3
values reported below the lower limit of quantitation
(LLOQ) or above the upper limit of quantitation (ULOQ)
were imputed by LLOQ/2 or 0 and by ULOQ or the
maximal value below the ULOQ, respectively. Statistical
analyses were performed by Novartis using R version 3.0.1
or later and SAS version 9.2 or later.
Results
Patient population
The patient population has been described in more detail
previously [10]. Briefly, a total of 198 patients were ran-
domized: 65 each to pasireotide LAR 40 and 60 mg, and
68 to continued treatment with octreotide LAR 30 mg or
lanreotide Autogel 120 mg (active control). Patient
demographics, characteristics and disease history were
generally similar across the three treatment groups at
baseline. In total, 59 (90.8 %), 57 (87.7 %), and 65
(95.6 %) patients in the pasireotide LAR 40 mg, pasireo-
tide LAR 60 mg, and active control groups completed the
24-week study, respectively.
Changes in GH, IGF-1, IGFBP-2, and IGFBP-3
levels
A decrease from baseline in GH, IGF-1, and IGFBP-3
levels was seen with both pasireotide and active control,
with the magnitude of decrease being higher in the pasir-
eotide LAR 40 and 60 mg groups. Mean baseline values
for GH, IGF-1, and IGFBP-3 were similar between pasir-
eotide LAR and active control; however, baseline values
for these parameters were lower among responders com-
pared with non-responders to pasireotide (Table 1; Fig. 1).
The overall median decrease from baseline to week 24 in
GH and IGF-1 levels was numerically greater in the
pasireotide LAR 60 mg group compared with the 40 mg
group, with this dose dependency being most apparent
among non-responders. Notably, decreases in both GH and
IGF-1 among non-responders were more marked in both
pasireotide arms compared with active control. For IGFBP-
2, the median (interquartile range [IQR]) percentage
changes from baseline in IGFBP-2 levels for pasireotide
LAR 40 mg (27 % [73 %]), 60 mg (36 % [86 %]) and
active control (25 % [85 %]) were similar at week 24
(Fig. 1). However, for pasireotide LAR 40 and 60 mg,
respectively, the median (IQR) percentage changes in
IGFBP-2 levels from baseline to week 24 were 66 %
(41 %) and 37 % (72 %) for treatment responders versus
26 % (80 %) and 33 % (91 %) for non-responders.
Changes in glycaemic biomarkers
In patients receiving pasireotide LAR 40 and 60 mg,
respectively, 44 and 49 % did not receive antidiabetic
medication during this study, 31 and 26 % were receiving
antidiabetic medication at study entry, and 25 and 25 % of
patients initiated antidiabetic medication during this study.
Patients who received antidiabetic medication during
pasireotide LAR treatment had higher baseline mean FPG
and HbA1c levels (Fig. 2) and more variable FPG levels
(Supplementary Fig. 1) than patients who received no
antidiabetic medication.
Effect of baseline glucose status on glucose
and HbA1c levels during treatment
Analysis of all patients revealed that those with baseline
FPG[ 100 mg/dL experienced higher values of FPG and
HbA1c after treatment with pasireotide LAR than patients
with baseline FPG levels B100 mg/dL (Fig. 3; Table 2).
Among patients not receiving antidiabetic medication at
baseline and with baseline FPG B 100 mg/dL, 30 % (6/20)
and 48 % (10/21) developed hyperglycaemia (FPG[
126 mg/dL) during treatment with pasireotide LAR 40 mg
and 60 mg, respectively. In contrast, 52 % (11/21) and 71 %
(15/21) of patients with baseline FPG[ 100 mg/dL devel-
oped hyperglycaemia during treatment (Fig. 4).
In the pasireotide LAR 40 mg treatment group, geo-
metric mean baseline FPG was 104.1 mg/dL (95 % CI
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91.9–117.8) and 105.6 mg/dL (95 % CI 101.0–110.5) for
responders and non-responders, respectively, which
increased to 124.4 mg/dL (95 % CI 115.0–134.6) and
123.8 mg/dL (95 % CI 113.4–135.2) at week 24 (median
[IQR] percentage change from baseline, 19.4 % [23.3 %]
and 10.7 % [16.5 %]). For the 60 mg dose of pasireotide,
responders and non-responders, respectively, had mean
baseline FPG levels of 100.7 mg/dL (95 % CI 88.3–114.7)
and 106.0 mg/dL (95 % CI 101.1–111.1), which increased
to 121.2 mg/dL (95 % CI 100.9–145.6) and 141.0 mg/dL
(95 % CI 127.5–155.8) at week 24 (median [IQR] per-
centage change from baseline, 19.4 % [36.5 %] and
24.5 % [27.0 %]).
The effect of pasireotide LAR treatment on HbA1c was
similar for responders and non-responders: the median
(IQR) percentage changes from baseline to week 24 for
responders were 9.2 % (19.1 %) and 10.6 % (7.7 %) for
pasireotide LAR 40 mg and 60 mg, respectively, and
6.7 % (12.1 %) and 12.1 % (20.5 %) for non-responders.
In addition to these findings, responder rates were found to
be very similar in patients who did (21 % [n = 13]) and
did not (19 % [n = 10]) receive antidiabetic medication.
Discussion
GH and IGF-1 are both closely linked to glycaemic status.
GH suppresses insulin-mediated glucose uptake and
enhances hepatic gluconeogenesis, while IGF-1, in addition
to enhancing insulin action, also suppresses GH secretion
[11]. These antagonistic effects act to modulate respon-
siveness to insulin. Sustained or excess GH secretion is
associated with insulin resistance in both physiological (in
healthy individuals during exercise and sleep) and patho-
logical (acromegaly) states [12, 13], while the association
between IGF-1 and insulin resistance is complex and
remains less well understood.
IGF-1 (and, indirectly, GH) is regulated by a family of
six homologous IGFBPs. Levels of IGFBP-3, the major
binding protein for IGF-1, increase in response to
increased levels of GH and IGF-1 [14, 15]. IGFBP-3 was
once considered to be a potential biochemical marker of
excess GH in patients with suspected acromegaly [16]. A
relationship between increased levels of IGFBP-3 and
hyperglycaemia has been suggested. In murine models,
IGFBP-3 inhibits insulin-stimulated glucose uptake [17],
Table 1 Effects of pasireotide and active control on GH, IGF-1, and IGFBP-3 after 24 weeks of treatment in all patients
Na Baseline geometric














week 24 for all
patients (%)
Pasireotide 40 mg
GH (ng/mL) 59 7.9 (6.0–10.3) 6.2 (4.2–9.0) 8.3 (6.1–11.4) 3.6 (2.5–5.3) -51.4 (39.8)
IGF-1
(ng/mL)
59 640.7 (586.1–700.3) 462.1 (391.6–545.3) 684.8 (625.2–750.1) 400.1 (335.3–477.3) -38.6 (54.9)
IGFBP-3
(lg/mL)
59 6.4 (6.1–6.6) 5.9 (5.4–6.6) 6.5 (6.2–6.7) 5.6 (5.2–5.9) -13.5 (22.1)
Pasireotide 60 mg
GH (ng/mL) 57 6.7 (5.2–8.7) 4.5 (3.3–6.1) 7.6 (5.5–10.4) 2.4 (1.7–3.5) -61.3 (43.0)
IGF-1
(ng/mL)
57 635.7 (582.5–693.8) 567.9 (484.1–666.3) 657.3 (593.7–727.6) 319.1 (266.1–382.6) -48.9 (42.2)
IGFBP-3
(lg/mL)
57 6.1 (5.9–6.4) 6.0 (5.5–6.6) 6.2 (5.9–6.5) 5.2 (4.8–5.6) -13.2 (21.1)
Pasireotide 40/60 mg
GH (ng/mL) 116 7.3 (6.0–8.8) 5.1 (4.0–6.6) 7.9 (6.4–9.9) 3.0 (2.3–3.9) -55.8 (45.6)
IGF-1
(ng/mL)
116 638.2 (599.8–679.2) 519.2 (460.1–586.0) 671.6 (627.7–718.7) 358.0 (315.1–406.8) -44.3 (48.7)
Active control
GH (ng/mL) 65 6.9 (5.7–8.2) – – 5.3 (4.1–6.8) -14.7 (52.7)
IGF-1
(ng/mL)
65 648.5 (594.3–707.7) – – 561.1 (508.2–619.5) -7.4 (32.3)
IGFBP-3
(lg/mL)
65 6.3 (6.1–6.6) – – 5.9 (5.6–6.2) -5.2 (18.1)
CI confidence interval, IQR interquartile range
a Number of patients with baseline measurements
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while over-expression of IGFBP-3 in male transgenic
mice results in fasting hyperglycaemia, impaired glucose
tolerance, and insulin resistance [18]. In the current
analysis, dose-dependent reductions in GH, IGF-1, and
IGFBP-3 levels were observed with pasireotide LAR,
with levels of all three markers remaining consistently
suppressed during the treatment period. When these
findings were stratified according to whether patients were
responders or non-responders to pasireotide LAR treat-
ment, the responder group had lower GH levels and lower
IGF-1 levels at baseline than the non-responder group.
This finding is consistent with a previous population
pharmacodynamic analysis of octreotide in patients with
acromegaly, in which high baseline GH levels were
associated with poorer responses to octreotide treatment
[19]. For IGFBP-3, baseline levels were similar in both
responders and non-responders.
Glucose homeostasis was relatively undisturbed
throughout the treatment period in those patients receiving
continued therapy with either octreotide or lanreotide. By
contrast, there was a rapid initial increase in mean glucose
and HbA1c levels following treatment with pasireotide
LAR, which subsequently plateaued, remaining stable to
24 weeks. This finding is consistent with previous Phase III
study observations in which pasireotide-associated
elevations in glucose levels typically plateaued after
Fig. 1 Effect of pasireotide LAR and active control on a GH, b IGF-1, c IGFBP-3, and d IGFBP-2 levels during 24 weeks of treatment in all
patients, responders, and non-responders. Data presented as geometric mean and 68 % CI. Inset values represent patient numbers at 24 weeks
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approximately 2–3 months of pasireotide treatment in
patients with acromegaly [20] and Cushing’s disease [21–
23]. Patients with baseline glucose levels [100 mg/dL
experienced higher levels of glucose and HbA1c after
treatment with pasireotide LAR compared with patients
with normoglycaemia at baseline. Although results vary,
the data suggest that baseline glucose status is a potential
predictive factor for the development of hyperglycaemia
during pasireotide LAR treatment.
Patients who received antidiabetic medication during
pasireotide LAR treatment had higher baseline mean glu-
cose and HbA1c levels than patients who received no
antidiabetic medication. Notably, approximately half of
patients treated with pasireotide LAR did not receive
antidiabetic medication at any time during this study. This
finding suggests that a substantial proportion of patients
with acromegaly do not experience disturbances in glucose
Fig. 2 Effect of pasireotide LAR and active control on a FPG and
b HbA1c levels in all patients, patients receiving antidiabetic
medication at any time point, patients not receiving antidiabetic
medication, patients receiving antidiabetic medication at baseline, and
patients starting antidiabetic medication post-baseline. Data presented
as geometric mean and 68 % CI. Inset values represent patient
numbers at 24 weeks
Endocrine (2016) 53:210–219 215
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homeostasis during pasireotide LAR treatment that war-
rants the initiation of antidiabetic medication.
Given the physiological role of natural somatostatin, as
well as the SSTR binding profile of pasireotide [24], dis-
turbances in glucose metabolism are not unexpected during
treatment with pasireotide. Endocrine cells of the pancreas
consist of a-, b-, and d-cells, which secrete glucagon,
insulin, and somatostatin, respectively, in response to
changes in blood glucose. Insulin and glucagon are
antagonistic hormones that regulate glucose uptake and
metabolism, while localized release of somatostatin sup-
presses secretion of insulin and glucagon. In humans,
glucagon-producing a-cells predominantly express SSTR2
[25], whereas SSTR5 and SSTR2 are found mainly on
insulin-producing b-cells [26]. As pasireotide binds with
higher affinity to SSTR5 than to SSTR2 [24], insulin
secretion is substantially reduced while glucagon secretion
is less markedly suppressed, resulting in an overall increase
Fig. 3 Effect of pasireotide LAR and active control on a FPG and b HbA1c in patients with baseline FPG B 100 or[100 mg/dL. Data presented
as geometric mean and 68 % CI. Inset values represent patient numbers at 24 weeks


























14.9 (14.1) 24 5.8 (5.6–6.0) 6.5 (5.9–6.4) 5.6 (11.1)




8.1 (24.1) 34 6.0 (5.8–6.2) 6.7 (6.3–7.1) 9.4 (11.1)
Pasireotide 60 mg




30.7 (33.9) 23 5.5 (5.3–5.6) 6.2 (5.8–6.6) 10.5 (13.7)




22.4 (26.7) 33 6.2 (5.9–6.5) 7.4 (6.8–8.0) 12.1 (21.0)
Active control




7.0 (9.6) 17 5.8 (5.6–6.1) 5.9 (5.6–6.2) -1.7 (8.8)




-2.26 (12.3) 44 6.0 (5.9–6.2) 6.1 (5.9–6.2) 0 (5.2)
a Number of patients with baseline measurements for FPG
b Number of patients with baseline measurements for HbA1c
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in glucose levels. Preclinical observations showed that
pasireotide and octreotide suppressed insulin secretion to a
similar degree, whereas pasireotide was a weaker inhibitor
of glucagon secretion than octreotide [27]. Indeed, the
SSTR5:SSTR2 activation ratio has been hypothesized to be
the main driver of pasireotide-induced hyperglycaemia
[27]. Schmid and Brueggen showed that co-administration
of octreotide with pasireotide in rats negated the hyper-
glycaemia seen with pasireotide alone, implying that strong
activation of SSTR2 by octreotide was sufficient to restore
normoglycaemia [27].
The mechanism of pasireotide-induced hyperglycaemia
has been explored in two studies conducted in healthy
human volunteers. Henry et al. reported that twice-daily
subcutaneous administration of 600 or 900 lg pasireotide
significantly decreased plasma levels of insulin, glucagon-
like peptide 1 (GLP-1), and glucose-dependent insulino-
tropic polypeptide [28]. Glucagon secretion was only
minimally affected, and insulin sensitivity was unaffected.
The effects of pasireotide on insulin (via SSTR5) and
glucagon secretion (via SSTR2) in this study were con-
sistent with the SSTR binding profile of pasireotide. In the
second study, the incretin-based antihyperglycaemic agents
liraglutide (a GLP-1 agonist) and vildagliptin (a dipeptidyl
peptidase 4 [DPP-4] inhibitor) were shown to effectively
ameliorate hyperglycaemia when co-administered with
pasireotide [29].
A similar finding has recently been reported for met-
formin-based antidiabetic therapy. In a sub-analysis of a
12-month, Phase III, randomized study in medically naı¨ve
patients with acromegaly [30], only those pasireotide
patients who initiated antidiabetic medication at some point
during the study, and not at baseline, were analysed
(n = 57). In line with its role as first-line medical therapy
for glycaemic management, metformin was the most
commonly initiated antidiabetic medication. Metformin
monotherapy (n = 24) or in combination with another oral
antidiabetic medication (n = 19) was found to be effective
in controlling (HbA1c\ 7 %) pasireotide-associated
hyperglycaemia. Although metformin exerts its therapeutic
effect mainly by reducing hepatic glucose production, it
also reduces DPP-4 activity and increases GLP-1 secretion,
which may be significant in the current context [31]. Taken
together with the aforementioned studies, the role of the
incretin system affecting insulin secretion is strongly
implicated in the mechanism of action of pasireotide.
Endogenous processes may also potentially reduce the
impact of pasireotide-induced hyperglycaemia. IGFBP-2 is
a regulator of IGF-1, blocking the ability of the latter to
bind to its receptor [32, 33], and it is also capable of
modulating cellular processes independently of IGF-1
binding [34]. Although the physiological role of IGFBP-2
is not well defined, over-expression of IGFBP-2 in a
transgenic mouse model was associated with improved
Fig. 4 Percentage of patients developing hyperglycaemia (post-
baseline FPG C 126 mg/dL or receiving antidiabetic medication
post-baseline) during treatment with pasireotide LAR or active
control, stratified by baseline FPG levels B 100 or[100 mg/dL, in
patients without baseline antidiabetic medication
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insulin sensitivity compared with wild type [35]. Although
data from the current analysis showed that responders to
pasireotide LAR had increased levels of IGFBP-2 during
treatment compared with non-responders, the effect of
pasireotide LAR on levels of glycaemic biomarkers was
found to be similar in both responders and non-responders.
Whether or not elevated levels of IGFBP-2 confer
increased insulin sensitivity, which may offset the effects
of pasireotide LAR on glucose homeostasis in this setting,
remains unknown. It is possible that the relatively short-
term duration of the primary study (6 months) was an
insufficient timeframe to observe such a phenomenon.
Conclusion
Pasireotide LAR has demonstrated superior efficacy over
octreotide LAR in medically naı¨ve patients with acrome-
galy and, in the PAOLA study, in patients with uncon-
trolled acromegaly versus continued treatment with
octreotide LAR or lanreotide Autogel. In both studies, a
majority of patients experienced elevations in blood glu-
cose levels with pasireotide treatment. Owing to the
mechanism of action of pasireotide, elevated blood glucose
despite improved efficacy is not unexpected.
Nevertheless, approximately half of patients with inad-
equately controlled acromegaly who completed the
24-week PAOLA study did not experience disturbances in
glucose homeostasis during pasireotide LAR treatment that
warranted the initiation of antidiabetic medication.
Responders to pasireotide LAR (mean GH levels
\2.5 lg/L and normalized IGF-1 levels) had lower GH and
IGF-1 levels at baseline than non-responders. The effect of
pasireotide LAR on blood glucose levels was similar in
both responders and non-responders at week 24 and
depended on the baseline glucose level.
Hyperglycaemia after pasireotide LAR treatment was
observed in some patients who were normoglycaemic at
baseline, but the effect was more pronounced in patients
with pre-existing hyperglycaemia. Pre-treatment glucose
status may thus be predictive of the development of
pasireotide-associated hyperglycaemia and could play a
future role in selecting appropriate or individualized ther-
apy in patients with acromegaly.
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